| 103909-75-7 Basic information More.. |
Product Name: | Maxacalcitol | Synonyms: | MAXACALCITOL;(5Z,7E)-9,10-Seco-22-oxacholesta-5,7,10(19)-triene-1α,3β,25-triol;22-Oxa-1α,25-dihydroxycholecalciferol;Oxacalcitriol;(+)-(5Z,7E)-(1S,3R,20S)-20-(3-Hydroxy-3-methylbutyloxy)-9,10-secopregna-5,7,10(19)-triene-1,3-diol;1,3-Cyclohexanediol, 4-methylene-5-[(2E)-2-[(1S,3aS,7aS)-octahydro-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3S,5Z)-;(1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1S,3aS,7aS)-octahydro-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol;(1R,3S,Z)-5-(2-((1S,3aS,7aS,E)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol | CAS: | 103909-75-7 | MF: | C26H42O4 | MW: | 418.61 | EINECS: | 234-317-2 | Mol File: | 103909-75-7.mol | |
Use
Maxacalcitol is the third synthetic vitamin D analog, after paricalcitol and
doxercalciferol, to be marketed for the treatment of secondary hyperparathyroidism (SHPT) associated with chronic renal failure. It is a new vitamin D3 derivative with an
oxygen atom in 22-position as main structural feature (22-oxacalcitriol, OCT). This vitamin
D receptor agonist has a strong inhibitory effect on synthesis and secretion of parathyroid
hormone in the setting of severe parathyroid hyperplasia. Maxacalcitol induced only minor
effects on calcium and phosphate metabolism unlike an agent such as 1, 25(OH)2D3 that
produced hypercalcemia and hyperphosphatemia. Maxacalcitol is.
- Maxacalcitol
-
- US $15.00-10.00 / KG
- 2021-07-13
- CAS:103909-75-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Maxacalcitol
-
- US $15.00-10.00 / KG
- 2021-07-09
- CAS:103909-75-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Maxacalcitol
-
- US $1.00 / KG
- 2019-12-27
- CAS:103909-75-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200kg
|
103909-75-7
Recommend Suppliers |
|